ArticleMedical microbiology and immunology2026
Epstein-Barr virus serological profiles and atypical patterns in a large tertiary-care cohort: a retrospective study of 11,503 patients.
Article in Medical microbiology and immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epstein-Barr virus (EBV) infection is highly prevalent worldwide, and its seroepidemiology varies according to age and sociodemographic factors. Recent observations suggest potential shifts in exposure dynamics following the COVID-19 pandemic and ongoing challenges in interpreting atypical antibody profiles. This retrospective study evaluated EBV serological patterns in 11,503 patients tested VCA IgM, VCA IgG, EA IgG, and EBNA IgG between January 2023 and August 2025 at a tertiary-care hospital. Patterns were classified as seronegative, primary infection, past infection, reactivation pattern, or atypical. Age- and sex-related distributions were analyzed using logistic regression. Past infection was the most frequent profile (64.0%), followed by seronegativity (19.8%) and atypical patterns (14.3%). VCA IgG seropositivity reached 53.2% in the 5-9 age group and increased with age. Age was strongly associated with EBV seropositivity, and female sex independently increased the odds of VCA IgG positivity. Atypical serological patterns were more common in younger individuals and showed an inverse association with age, while sex had no independent effect. Isolated VCA IgG positivity was the most common atypical pattern. These findings provide updated data on EBV serological patterns in a large tertiary-care cohort during the post-pandemic period. The observed age-specific seropositivity rates may suggest a trend toward later EBV exposure; however, the absence of a direct pre-pandemic comparator requires cautious interpretation. Accurate interpretation of atypical EBV serological profiles remains important in clinical practice and should consider patient age, timing of antibody responses, and analytical characteristics of the assay.
Indexed as
Identifiers
42611133What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.